| 大葉大學 |
2009-11-13 |
Between the Lines: Phonetic Modeling of Incidentally Acquired Word Meanings
|
Troy, Carol;Tsau, Syou-Rung |
| 淡江大學 |
2016-06 |
Between the Myth of Development and the Development of Myth: Futures of Islamic Banking in the Gulf Cooperation Council (GCC)
|
Nedal, El-Ghattis |
| 臺大學術典藏 |
1986 |
Between Tradition and Morality: Value Orientations of Farmers in Taiwan
|
Chun-chieh Huang; Chun-chieh Huang |
| 國立高雄師範大學 |
2001 |
Between Traditional and Generative Grammar
|
澤田深雪; Miyuki Sawada |
| 國立政治大學 |
2013-07 |
Between Translation and Transformation: Examining the German Translation of E-PLAN Scripts from the Perspective of Functional Translation
|
徐安妮; Hsu, An-Nie |
| 臺北市立大學 |
2019 |
Between Two Mediating Texts: Chinese Translations of The Adventures of Pinocchio in the 20th Century
|
Chen, Hung-Shu；陳宏淑 |
| 國立臺灣師範大學 |
2015-09-03T01:09:18Z |
Between Two Worlds
|
路愷宜 |
| 國立政治大學 |
2011-03 |
Between Two “Homelands”:The Image of Mashugi Shizue's Writing about Colonial Taiwan in the 1940s
|
吳佩珍 |
| 國立中山大學 |
2005-7 |
Between “Homeworld” and “Alienworld”: Waldenfels on Interculturality
|
游淙祺 |
| 國立政治大學 |
2014-12 |
Between ＂May Fourth＂ and ＂June Fourth＂: ＂April Fifth＂ as a Forgotten Revolutionary Tradition at Tiananmen Square and Its Political Use
|
潘宗億; Pan, Tsung-Yi |
| 國立成功大學 |
2020-12-3 |
Between-module functional connectivity of the salient ventral attention network and dorsal attention network is associated with motor inhibition
|
Hsu;Muchen, Howard;Yao;Zai-Fu;Hwang;Kai;Hsieh;Shulan |
| 國立中山大學 |
2001-06-06 |
Betwixt the Text and the Tenor: Promiscuous Liminality of English in Derek Walcott’s Poetry
|
Ting-yao Luo |
| 國立成功大學 |
2024-01-22 |
BET抑制劑在Doxorubicin治療下對心肌細胞的影響及機制
|
吳柏鴻; Wu, Po-Hung |
| 臺北醫學大學 |
2005 |
Bevacizumab (Avastin) plus Chemotherapy in the Treatment of Metastatic Colorectal Carcinoma—A Multi-institutional Experience in Taiwan
|
戴承正; Tai CJ |
| 國立成功大學 |
2022 |
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
|
Shao, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Yang, T.-S.;Shen, Y.-C.;Chao, Y.;Chen, J.-S.;Su, C.-Y.;Chen, W.-J.;Hsiang, Hsiang H.-L.;Hsu, C.-H. |
| 國立臺灣海洋大學 |
2016-03 |
Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts
|
Po-Lei Wei; Yu-Jia Chang; Chun-Chao Chang; Hung-Yi Chiou; Chang-Jer Wu; Cheng-Jeng Tai; Hang Wang; Chien-Kai Wang; Chen-Jei Tai; Ming-Te Huang; Chih-Hsiung Wu; Ray-Jade Chen; Li-Jen Kuo |
| 臺大學術典藏 |
2018-09-10T18:03:32Z |
Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema
|
Hsieh, Y.-T.;Yang, C.-M.;Chang, S.-H.; CHUNG-MAY YANG; SHU-HUI CHANG |
| 臺大學術典藏 |
2020-05-21T02:19:06Z |
Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema
|
Hsieh, Yi-Ting;Chung-May Yang;Shu-Hui Chang; Hsieh, Yi-Ting; CHUNG-MAY YANG; SHU-HUI CHANG |
| 臺大學術典藏 |
2022-05-03T06:19:24Z |
Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema
|
Hsieh Y.-T.; Yang C.-M.; SHU-HUI CHANG |
| 臺大學術典藏 |
2022-07-15T06:43:04Z |
Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema
|
Hsieh Y.-T.; CHUNG-MAY YANG; Chang S.-H. |
| 臺大學術典藏 |
2021-05-03T02:20:41Z |
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
|
Andr? T.;Vernerey D.;Im S.A.;Bodoky G.;Buzzoni R.;Reingold S.;Rivera F.;Mckendrick J.;Scheithauer W.;Ravit G.;Fountzilas G.;Yong W.P.;Isaacs R.;?Sterlund P.;Jin-Tung Liang;Creemers G.J.;Rakez M.;Van Cutsem E.;Cunningham D.;Tabernero J.;De Gramont A.; Andr? T.; Vernerey D.; Im S.A.; Bodoky G.; Buzzoni R.; Reingold S.; Rivera F.; McKendrick J.; Scheithauer W.; Ravit G.; Fountzilas G.; Yong W.P.; Isaacs R.; ?sterlund P.; JIN-TUNG LIANG; Creemers G.J.; Rakez M.; Van Cutsem E.; Cunningham D.; Tabernero J.; de Gramont A. |
| 臺大學術典藏 |
2020-01-22T07:50:23Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Chiang Y.-C.; CHI-AN CHEN; Cheng W.-F.; Lee S.-P.;Hsu H.-C.;Tai Y.-J.;Chen Y.-L.;Chiang Y.-C.;Chi-An Chen;Cheng W.-F.; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L. |
| 臺大學術典藏 |
2020-02-06T05:21:47Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; WEN-FANG CHENG; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; WEN-FANG CHENG; WEN-FANG CHENG;Chen C.-A.;Chiang Y.-C.;Chen Y.-L.;Tai Y.-J.;Hsu H.-C.;Lee S.-P.; Lee S.-P. |
| 臺大學術典藏 |
2020-02-14T02:49:36Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.;Hsu H.-C.;Tai Y.-J.;Chen Y.-L.;Chiang Y.-C.;Chen C.-A.;Wen-Fang Cheng; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; WEN-FANG CHENG |
| 臺大學術典藏 |
2020-02-14T08:50:30Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P; Hsu H.-C; Tai Y.-J; Chen Y.-L; YING-CHENG CHIANG; Chen C.-A; Cheng W.-F. |
| 臺大學術典藏 |
2020-05-24T06:00:15Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; Hsu H.-C.; Tai Y.-J.; YU-LI CHEN; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-02-04T02:39:51Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.;Hsu H.-C.;Tai Y.-J.;Yu-Li Chen;Chiang Y.-C.;Chen C.-A.;Cheng W.-F.; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; YU-LI CHEN; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-02-04T06:11:34Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; Hsu H.-C.; YI-JOU TAI; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-02-04T07:44:50Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; YING-CHENG CHIANG; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-09-27T06:18:43Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; HENG-CHENG HSU; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-03-10T02:34:33Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.;Heng-Cheng Hsu;Tai Y.-J.;Chen Y.-L.;Chiang Y.-C.;Chen C.-A.;Cheng W.-F.; Lee S.-P.; HENG-CHENG HSU; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 國立臺灣大學 |
2009 |
Bevacizumab for the Treatment of Corneal Neovascularization
|
陳偉勵; 陳彥名; 朱筱桑; 蔡紫筠; 胡芳蓉; CHEN, WEI-LI; CHEN, YAN-MING; CHU, HSIAO-SANG; TSAI, TZU-YUN; HU, FUNG-RONG |
| 臺大學術典藏 |
2020-10-22T07:41:52Z |
Bevacizumab for the treatment of corneal neovascularization
|
Hu F.-R.; Lin Y.-H.; Tsai T.-Y.; Chu H.-S.; Chen Y.-M.; WEI-LI CHEN |
| 臺大學術典藏 |
2022-07-15T08:17:47Z |
Bevacizumab for the treatment of corneal neovascularization
|
Chen W.-L.; Chen Y.-M.; Chu H.-S.; Lin Y.-H.; Tsai T.-Y.; FUNG-RONG HU |
| 臺大學術典藏 |
2020-05-26T09:26:21Z |
Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?
|
Chih-Hsin Yang; CHIH-HSIN YANG |
| 國立臺灣大學 |
2009 |
Bevacizumab Is Not Toxic to Retinal Ganglion Cells after Repeated Intravitreal Injection
|
鄭成國; 彭百慧; 田履黛; 陳朝峰; 李憶菁; CHENG, CHENG-KUO; PENG, PAI-HUEI; TIEN, LU-TAI; CHEN, CHAU-FONG; LEE, YIH-JING |
| 國立臺灣大學 |
2016 |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen, I-Chun; Lin, Ching-Hung; Jan, I-Shiow; Cheng, Ann-Lii; Lu, Yen-Shen; 盧彥伸; 林璟宏; 詹一秀; 陳怡君; 鄭安理; 林季宏 |
| 臺大學術典藏 |
2018-09-10T09:41:56Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen, I-Chun;Lin, Ching-Hung;Jan, I-Shiow;Cheng, Ann-Lii;Lu, Yen-Shen;林季宏; Chen, I-Chun;Lin, Ching-Hung;Jan, I-Shiow;Cheng, Ann-Lii;Lu, Yen-Shen; Chen, I-Chun;Lin, Ching-Hung;Jan, I-Shiow;Cheng, Ann-Lii;Lu, Yen-Shen; 盧彥伸;林璟宏;詹一秀;陳怡君;鄭安理;林季宏; I-SHIOW JAN; Kao, Jia-Horng; Chen, I-Chun; Lin, Ching-Hung; CHING-HUNG LIN; Lin, Ching-Hung; ANN-LII CHENG; Jan, I-Shiow; Jan, I-Shiow; Cheng, Ann-Lii; Cheng, Ann-Lii; Lu, Yen-Shen; Lu, Yen-Shen; 高嘉宏 |
| 臺大學術典藏 |
2020-05-25T06:51:50Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen I.-C;Lin C.-H;Jan I.-S;Cheng A.-L;Yen-Shen Lu; Chen I.-C; Lin C.-H; Jan I.-S; Cheng A.-L; YEN-SHEN LU |
| 臺大學術典藏 |
2021-08-16T03:26:39Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
I-CHUN CHEN; Lin C.-H.; Jan I.-S.; Cheng A.-L.; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:44Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen I.-C.; Lin C.-H.; Jan I.-S.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-03-12T00:50:54Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen I.-C.; Lin C.-H.; I-SHIOW JAN; Cheng A.-L.; Lu Y.-S. |
| 臺北醫學大學 |
2012 |
Bevacizumab plus Docetaxel and Cisplatin for Metastatic Breast Cancer: A Pilot Phase II Study
|
CJ, Tai;CS, Chen;CS, Hung;LJ, Kuo;PL, Wei;JF, Chiou;CH, Hsu;HY, Chiou;CH, Wu |
| 國立臺灣大學 |
2015 |
Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy
|
Lu, Yen-Shen; Chen, Tom Wei-Wu; Lin, Ching-Hung; Yeh, Dah-Cherng; Tseng, Ling-Ming; Wu, Pei-Fang; Rau, Kun-Ming; Chen, Bang-Bin; Chao, Ta-Chung; Huang, Shu-Min; Huang, Chiun-Sheng; Shih, Tiffany Ting-Fang; Cheng, Ann-Lii; 林志弘; 陳偉武; 盧彥伸; 林璟宏; 施庭芳; 吳佩芳; 鄭安理; 陳邦斌; 黃俊升; 林季宏 |
| 臺大學術典藏 |
2015 |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Cheng A.-L.; Shih T.T.-F.; CHIUN-SHENG HUANG; Huang S.-M.; Chao T.-C.; Chen B.-B.; Rau K.-M.; Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2020-05-25T06:51:53Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Shih T.T.-F; Cheng A.-L; Taiwan Breast Cancer Consortium; Huang C.-S; Huang S.-M; Chao T.-C; Chen B.-B; Rau K.-M; Wu P.-F; Tseng L.-M; Yeh D.-C; Lin C.-H; Chen T.W.-W; YEN-SHEN LU; Taiwan Breast Cancer Consortium;Cheng A.-L;Shih T.T.-F;Huang C.-S;Huang S.-M;Chao T.-C;Chen B.-B;Rau K.-M;Wu P.-F;Tseng L.-M;Yeh D.-C;Lin C.-H;Chen T.W.-W;Yen-Shen Lu |
| 臺大學術典藏 |
2020-08-06T07:51:48Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.;Chen T.W.-W.;Lin C.-H.;Yeh D.-C.;Tseng L.-M.;Wu P.-F.;Rau K.-M.;Chen B.-B.;Chao T.-C.;Huang S.-M.;Huang C.-S.;Tiffany Ting-Fang Shih;Cheng A.-L.;Taiwan Breast Cancer Consortium; Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; TIFFANY TING-FANG SHIH; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2022-03-15T05:39:30Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; WEI-WU CHEN; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-03-18T03:23:37Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; WEI-WU CHEN; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-08-31T06:29:51Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; ANN-LII CHENG; Taiwan Breast Cancer Consortium |
